主管单位:中华人民共和国
国家卫生健康委员会
主办单位:中国医师协会
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文关键词:
目的 探讨强化剂量阿托伐他汀对经皮冠状动脉介入(PCI)术后老年患者血脂及血清高敏C反应蛋白(hs-CRP)水平的影响。方法 选取2016年7月至2017年7月于海南省人民医院行PCI术的68例冠状动脉粥样硬化性心脏病患者作为研究对象,采用抛硬币法随机分为观察组和对照组,每组34例。对照组患者在常规治疗基础上给予阿托伐他汀10 mg口服治疗,每晚1次;观察组患者在常规治疗基础上给予阿托伐他汀80 mg口服治疗,每晚1次。比较2组患者治疗前后总胆固醇、三酰甘油、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及hs-CRP水平。结果 治疗前,2组患者总胆固醇、三酰甘油、LDL-C及HDL-C水平比较,差异均无统计学意义(均P>0.05)。2组患者治疗后总胆固醇、三酰甘油、LDL-C水平均明显低于治疗前,HDL-C水平均明显高于治疗前,且观察组患者治疗后总胆固醇、LDL-C水平明显低于对照组,HDL-C水平明显高于对照组,差异均有统计学意义(均P<0.05)。治疗前,观察组与对照组hs-CRP水平比较[(11.2±5.2)mg/L比(10.8±5.1)mg/L],差异无统计学意义(P>0.05),治疗后,观察组与对照组患者的hs-CRP水平[(4.2±1.8)、(7.0±2.9)mg/L]均明显低于本组治疗前,且观察组患者hs-CRP水平明显低于对照组,差异均有统计学意义(均P<0.05)。结论 强化剂量阿托伐他汀应用于PCI术后老年患者能有效降低血脂及hs-CRP水平,增强抗炎作用。
【Abstract】Objective To analyze the effect of enhanced dose atorvastatin on serum lipid and high-sensitivity C-reactive protein(hs-CRP) in elderly patients after percutaneous coronary intervention(PCI). Methods A total of 68 cornary heart disease patients undergoing PCI from July 2016 to July 2017 in Hainan General Hospital were randomly divided into observation group(n=34) and control group(n=34). The control group took atorvastatin 10 mg every evening; the observation group took atorvastatin 80 mg every evening. Levels of total cholesterol, triacylglycerol, low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C) and hs-CRP were analyzed before and after treatment. Results There were no significant differences of total cholesterol, triacylglycerol, LDL-C and HDL-C levels between groups before treatment(P>0.05). After treatment, levels of total cholesterol, triacylglycerol and LDL-C were significantly lower and HDL-C was significantly higher than those before treatment in both groups; levels of total cholesterol and LDL-C in observation group were significantly lower and HDL-C was significantly higher than those in control group(P<0.05). Level of hs-CRP before treatment had no significant difference between observation group and control group[(11.2±5.2)mg/L vs (10.8±5.1)mg/L](P>0.05). After treatment, level of hs-CRP was significantly lower than that before treatment in both groups; level of hs-CRP in observation group[(4.2±1.8)mg/L] was significantly lower than that in control group[(7.0±2.9)mg/L](P<0.05). Conclusion Enhanced dose atorvastatin treating elderly patients after PCI can effectively reduce serum lipid, hs-CRP level and improve the anti-inflammatory action.
【Key words】Percutaneous coronary intervention;Atorvastatin;High-sensitivity C-reactive protein
copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。